# A short guide to PBPK model development, evaluation, simulations and documentation

The versatile nature of physiologically based pharmacokinetic (PBPK) modeling facilitates many opportunities of application but at the same time also for different approaches in terms of execution. This inevitably introduces the questions on way of working and best practices. How should model development, including challenges addressed and assumptions made, be conducted and reported? How should analyses be performed at different stages in drug development to ensure robust results with confidence, reproducibility and traceability? To guide the users of the OSP-Suite we here present our view on best practices for PBPK modeling. The material is categorized under the sections Development, Evaluation, Application&Simulation and Documentation  including a repository of relevant literature to facilitate further reading on the topic.  

FIGURE - RM

To note, there are a number of existing review, overview, tutorial, and guidances available to the PBPK Community. This site is not intended to rewrite those materials but instead to serve as a landing page for individuals seeking to learn or to branch further into PBPK modeling. A sampling of existing learning content is listed below:

- FDA Meeting: *Development of Best Practices in Physiologically Based Pharmacokinetic Modeling to Support Clinical Pharmacology Regulatory Decision-Making.* [FDA Meeting](https://www.fda.gov/drugs/news-events-human-drugs/development-best-practices-physiologically-based-pharmacokinetic-modeling-support-clinical)
  
- Peters and Dolgos. *Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.* [https://doi.org/10.1007/s40262-019-00790-0 ](https://doi.org/10.1007/s40262-019-00790-0)

- FDA Guidance: *Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry.* [https://www.fda.gov/media/101469/download](https://www.fda.gov/media/101469/download)

- *EMA Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation.*  [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf)

- FDA DRAFT Guidance: *The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls.* [https://www.fda.gov/media/142500/download](https://www.fda.gov/media/142500/download)

- Shebley et al. *Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.* [https://doi.org/10.1002/cpt.1013 ](https://doi.org/10.1002/cpt.1013 )

- Miller et al. *Physiologically Based Pharmacokinetic Modelling for First‐In‐Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.* [https://doi.org/10.1007/s40262-019-00741-9](https://doi.org/10.1007/s40262-019-00741-9) 

- OECD: *Guidance Document on the Characterisation, Validation and Reporting of PBK Models For Regulatory Purposes (2021).* [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV-CBC-MONO(2021)1%20&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV-CBC-MONO(2021)1%20&doclanguage=en)